NCT06625593 2026-04-16
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
6 trialsNCT05566795 2026-03-02
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals, Inc.
Phase 3 Recruiting
NCT06877533 2025-08-12
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Terminated
NCT04004910 2022-03-24
A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients
Immunicom Inc
Phase 1/2 Unknown
NCT04278469 2020-02-20
Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy
Gencurix, Inc.
Phase NA Recruiting
NCT02462265 2018-04-18
Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients
Oshadi Drug Administration
Phase 2 Suspended